DMAC

Diamedica Therapeutics INC

-$17.0M

Net Activity

Institutions Holding

98

Popularity Rank

#4488

Avg Weight

0.11%

Total Value

$79.4M

Ownership Trend

98 institutions currently hold DMAC, with 45 net buyers and 37 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

37

Net Buying Institutions

45

Key Holders

View all 98 holding institutions

Quarterly Activity

Recent Activity

+$30.8M

Total Buy Value

$30.9M

Total Sell Value

New buy17
Trim25
Add28
Sold out12

45

Net Buyers

37

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding DIAMEDICA THERAPEUTICS INC (DMAC)?
Major stakeholders currently include Cooperman Leon G ($13.7M), BlackRock, Inc. ($12.6M), Millennium Management LLC ($6.3M). Based on the latest 13F filings, there are a total of 98 tracked investment funds and institutions maintaining positions in DMAC.
What is the overall institutional sentiment toward DMAC recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $17.0M, driven by 45 managers accumulating shares while 37 reduced their exposure.
Which institutions have been selling or reducing their DMAC positions?
In the latest period, 25 funds trimmed their holdings, and 12 managers completely exited their positions. The aggregate reported sell value was $30.9M.
Are there any notable investors adding DMAC to their portfolios?
Yes, buying activity remains notable. 17 institutions opened new positions in {ticker}, and 28 existing holders added to their shares. The total reported buy value for the quarter amounted to $30.8M.

Related Stocks